Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Heres

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
BMC Psychiatry|February 25, 2017
Shared decision making PLUS - a cluster-randomized trial with inpatients suffering from schizophrenia (SDM-PLUS)Johannes Hamann, Fabian Holzhüter, Lynne Stecher, et al.
The International Journal of Neuropsychopharmacology|January 7, 2011
Evidence-based pharmacotherapy of schizophreniaStefan Leucht, Stephan Heres, Werner Kissling, et al.
Psychopharmacology|February 9, 2023
Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gainKorbinian Felix Schreyer, Stefan Leucht, Stephan Heres, et al.
Schizophrenia Bulletin|July 28, 2016
Dose Equivalents for Antipsychotic Drugs: The DDD MethodStefan Leucht, Myrto Samara, Stephan Heres, et al.
Schizophrenia Bulletin|February 1, 2008
Methodological issues in current antipsychotic drug trialsStefan Leucht, Stephan Heres, Johannes Hamann, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 6, 2010
How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?Johannes Hamann, Rosmarie Mendel, Stephan Heres, et al.
International Clinical Psychopharmacology|August 11, 2007
The attitude of patients towards antipsychotic depot treatmentStephan Heres, Florian Simon Schmitz, Stefan Leucht, et al.
International Clinical Psychopharmacology|May 13, 2014
Pharmacokinetics of olanzapine long-acting injection: the clinical perspectiveStephan Heres, Susanne Kraemer, Richard F Bergstrom, et al.
The Journal of Nervous and Mental Disease|July 3, 2013
Clinicians' attitudes toward the use of long-acting injectable antipsychoticsLudovic Samalin, Thomas Charpeaud, Olivier Blanc, et al.
The American Journal of Psychiatry|February 2, 2006
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychoticsStephan Heres, John Davis, Katja Maino, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
BMC Psychiatry|February 25, 2017
Shared decision making PLUS - a cluster-randomized trial with inpatients suffering from schizophrenia (SDM-PLUS)Johannes Hamann, Fabian Holzhüter, Lynne Stecher, et al.
The International Journal of Neuropsychopharmacology|January 7, 2011
Evidence-based pharmacotherapy of schizophreniaStefan Leucht, Stephan Heres, Werner Kissling, et al.
Psychopharmacology|February 9, 2023
Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gainKorbinian Felix Schreyer, Stefan Leucht, Stephan Heres, et al.
Schizophrenia Bulletin|July 28, 2016
Dose Equivalents for Antipsychotic Drugs: The DDD MethodStefan Leucht, Myrto Samara, Stephan Heres, et al.
Schizophrenia Bulletin|February 1, 2008
Methodological issues in current antipsychotic drug trialsStefan Leucht, Stephan Heres, Johannes Hamann, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 6, 2010
How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?Johannes Hamann, Rosmarie Mendel, Stephan Heres, et al.
International Clinical Psychopharmacology|August 11, 2007
The attitude of patients towards antipsychotic depot treatmentStephan Heres, Florian Simon Schmitz, Stefan Leucht, et al.
International Clinical Psychopharmacology|May 13, 2014
Pharmacokinetics of olanzapine long-acting injection: the clinical perspectiveStephan Heres, Susanne Kraemer, Richard F Bergstrom, et al.
The Journal of Nervous and Mental Disease|July 3, 2013
Clinicians' attitudes toward the use of long-acting injectable antipsychoticsLudovic Samalin, Thomas Charpeaud, Olivier Blanc, et al.
The American Journal of Psychiatry|February 2, 2006
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychoticsStephan Heres, John Davis, Katja Maino, et al.
Pageof 9